PROteolysis-Targeting Chimeras (PROTACs) in leukemia: overview and future perspectives.

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Leukemia is a complex group of blood cancers with significant unmet needs due to treatment resistance and side effects.
• Conventional therapies like chemotherapy and immunotherapy have limitations, necessitating novel therapeutic strategies.
• Targeted protein degradation is emerging as a promising approach for personalized leukemia treatment.

Purpose of the Study:

• To review the current landscape of PROteolysis-TArgeting Chimeras (PROTACs) for leukemia treatment.
• To discuss the mechanism, development, and clinical potential of antileukemic PROTACs.
• To highlight the advantages and challenges of using PROTACs in managing leukemia.

Main Methods:

• Review of scientific literature on PROTACs in leukemia drug discovery.
• Critical analysis of chemical structures, in vitro/in vivo activities, pharmacokinetics, and pharmacodynamics of antileukemic PROTACs.
• Examination of ongoing clinical trials and future perspectives for PROTACs in leukemia therapy.

Main Results:

• PROTACs demonstrate potential in selectively degrading leukemia-associated proteins via the ubiquitin-proteasome system.
• Antileukemic PROTACs show promise in overcoming therapeutic resistance and reducing side effects associated with conventional treatments.
• The development of PROTACs is rapidly advancing, with several compounds showing significant preclinical and early clinical activity.

Conclusions:

• PROTACs represent a revolutionary therapeutic strategy with the potential to significantly improve outcomes for leukemia patients.
• Further research and clinical trials are crucial to fully realize the potential of PROTACs as next-generation leukemia drugs.
• PROTAC technology offers a promising avenue for personalized medicine in the treatment of diverse leukemic conditions.